SHENZHEN Hemogen Therapeutic Co., Ltd.

The envelope protein of a lentiviral vector (LV) determines its transduction specificity. Thus, optimally selected and modified envelope protein can effectively improve the specificity and transduction efficiency of the LV to target cells. In our TarVAb platform, the envelope protein is conjugated to antibody and it can specifically recognize and bind to the receptors on the surface of target cells.

Targeted vectors provide a promising approach for in vivo gene therapy, with enhanced therapeutic effect and safety and lowered cost. Beyond that, targeted vectors could provide customized delivery platforms in the fields of neurodegenerative disease treatment, CAR-T cell therapy, and monoclonal antibody preparation. Advancement in targeted gene therapy could also facilitate the development of oncolytic virus therapy. In summary, TarVAb platform would greatly expand the application scope of gene therapy tools.